During the first few days of acute lung injury in the newborn, the predominant inflammatory cell recruited into the lung is the PMN, and the level of influx of these cells is predictive of BPD (1, 2) . PMNs are now known to be more than effector cells; they have the ability to amplify recruitment of PMNs and inflammation by the release of chemokines (3, 4) . IL-8 and MIP are two potent chemokines, released by PMNs, that have been detected in the airway fluid of newborns early in the development of BPD (5, 6) . The release of these chemokines is thought to be under the control of a pivotal proinflammatory transcription factor, NF-B (7). In the PMN, the unique control of activity and cellular location of NF-B is now being studied with great intensity (8) . In our previous work, using PMNs of the newborn, dexamethasone was shown to inhibit NF-B activity and the release of these chemokines (9) .
There is an urgent need to find safe and effective antiinflammatory therapy, as an alternative to past dexamethasone practices, for the treatment of BPD (10) . IL-10 is a potent antiinflammatory cytokine that is produced by macrophages and possibly neutrophils and other lung cells (11) . There is evi-dence that IL-10 can suppress many proinflammatory functions of the PMN, but IL-10 may not be produced in sufficient quantity in the newborn to suppress inflammation (12) . Therapy with exogenous recombinant IL-10 has been started experimentally in certain inflammatory diseases of the adult but not yet for the newborn (13) . Therefore, the specific aims of the present study were to determine whether IL-10 is a potent inhibitor of chemokine release from neutrophils of the newborn and whether its mechanism of action was caused by inhibition of NF-B activity.
METHODS

Subjects
Cord blood (approximately 30 mL) was obtained from the placenta immediately after elective, cesarean section delivery of 11 term infants, without exposure to general anesthesia. Blood was collected in heparinized, preservative-free tubes for transport to the laboratory, followed by immediate PMN isolation. The study was approved by the Human Subjects Review Committee of the North Shore-Long Island Jewish Health Care System.
PMN Isolation and Culture Protocol
PMNs were isolated under endotoxin-free conditions using Ficoll-Paque and dextran (Pharmacia, Piscataway, NJ, U.S.A.) centrifugation and sedimentation, respectively, followed by hypotonic lysis of the residual erythrocytes as described previously (14) . The isolated cells contained more than 98% PMNs, and the cells were 99% viable as determined by trypanblue exclusion. Purified cells were resuspended in RPMI 1640 supplemented with 10% FCS (Life Technologies, Grand Island, NY, U.S.A.) to obtain a final concentration of 5 ϫ 10 6 cells/mL at 37°C. Cells were exposed to serial doses of purified, recombinant IL-10 (R&D Systems, Minneapolis, MN, U.S.A.) and incubated at 37°C for 1 h before stimulation with LPS (Sigma Chemical Co., St. Louis, MO, U.S.A.) or recombinant TNF (R&D Systems) for 18 h in polystyrene 96-well culture plates. Based on previous work from our laboratory, we used submaximal, physiologic doses of TNF (1 ng/mL) and LPS (10 ng/mL) to stimulate the release of IL-8 and MIP (15) .
We used a near-maximal inhibitory dose of IL-10, from the dose-response studies above, to assess NF-B activity (at 30 min) and I-B␣ protein expression at 30 min and 3 h after stimulation of PMNs with LPS. These times were chosen on the basis of previous studies showing NF-B activation at 30 min (8) . We also determined I-B␣ expression at 3 h, because a recent study using neutrophils from adults indicated the effect of IL-10 on neutrophils may need a 3-h exposure (16) .
Measurements
ELISA for IL-8 and MIP. Release of IL-8 and MIP from PMNs was measured in cell culture supernatants using commercially available ELISA kits (R&D Systems) as previously described (3).
EMSA for NF-B activity. Nuclear extracts were prepared from 5 ϫ 10 6 PMNs for EMSA as previously described (8, 9) . The nuclear extracts were incubated (20 min at room temperature) with 10 fmol of 32 P-labeled NF-B oligonucleotide (5'-TTGTTACAAGGGGACTTTCCGCTGGG-GACTTTCCAGGGAG-GC-3') in 20 L of binding buffer (20 mM Tris-Cl, pH 7.5, 150 mM KCl, 1 mM EDTA, 1 mM DTT, 0.1% NP-40, 6% glycerol) supplemented with 20 g of acetylated BSA and 2 g of poly-deoxyinosinedeoxycytosine. The resulting complexes were resolved on 5% nondenaturing polyacrylamide gels in 0.5ϫ Tris-Borate-EDTA buffer at 180 V for 2.5 h. The gels were dried and exposed to autoradiographic film (Kodak Biomax MS; Kodak, Rochester, NY, U.S.A.) with intensifier screen at Ϫ80°C overnight.
Western analysis for I-B␣ levels. This procedure has been previously described in detail from our laboratory (8) . Cytoplasmic extracts were prepared from PMNs stimulated with TNF or LPS in the presence or absence of IL-10, with separation of proteins on 12% SDS-PAGE, followed by transfer to a nitrocellulose membrane. The membranes were washed with Tris-buffered saline-Tween (20 mM Tris-Cl, pH 7.6, 1.37 mM NaCl, 0.05% Tween 20), blocked in Tris-buffered salineTween containing 5% nonfat dry milk (Tris-buffered salineTween-milk) for 2 h, and incubated 1 h at 25°C with I-B␣ primary antibody (SC-371; Santa Cruz Biochemicals, Santa Cruz, CA, U.S.A.) diluted (1:200) in Tris-buffered salineTween-milk. After washing in Tris-buffered saline-Tween, the membranes were incubated (1 h, 25°C) with anti-rabbit secondary antibody conjugated to horseradish peroxidase and developed using enhanced chemiluminescence detection (Amersham, Piscataway, NJ, U.S.A.). To confirm equal amounts of loaded proteins, the membranes were stripped and reprobed with actin antibody as described previously (8) .
Statistical Analyses
Results are expressed as mean Ϯ SEM. Statistical analyses were performed using ANOVA and the Mann-Whitney U test, with an overall significance level of 0.05 before Bonferroni correction for multiple comparisons (serial doses of IL-10).
RESULTS
Figures 1 and 2 demonstrate the effect of serial doses of IL-10 on the release of IL-8 and MIP, respectively, from PMNs stimulated with TNF. There was a trend toward inhibition of chemokine release by IL-10, but the results were not statistically significant for 1, 10, and 100 ng/mL (p Ͼ 0.05, n ϭ 4).
In contrast, Figures 3 and 4 demonstrate the effect of serial doses of IL-10 on the release of IL-8 and MIP, respectively, from PMNs stimulated with LPS. There was a statistically significant and marked inhibition of both IL-8 and MIP release with exposure to IL-10 starting at 1 ng/mL (p Ͻ 0.01). Therefore IL-10 at a dose of 10 ng/mL was selected as a near-maximal dose for studying the effect of IL-10 on NF-B activity and I-B␣ levels in subsequent experiments.
Activation of NF-B was directly measured by EMSA and indirectly measured by Western blot analysis of I-B␣ levels at To determine whether IL-10 inhibition of chemokines was caused by a delayed inhibition of NF-B, we examined I-B␣ levels with two stimulating doses of LPS (10 ng and 100 ng) at 30 min (Fig. 6) and 3 h (Fig. 7) . The results show that even at lower doses of LPS-induced PMN stimulation (10 and 100 ng/mL), IL-10 did not have any effect on I-B␣ degradation after 30 min (Fig. 6) . After 3 h of stimulation with LPS, I-B␣ cytoplasmic levels were restored as a result of the NF-Binduced neosynthesis of I-B␣ (Fig. 7) . However, IL-10 again had no significant effect on the resynthesis of new I-B␣. 
DISCUSSION
Antiinflammatory cytokine therapy may become a growing field of research in neonatal-perinatal medicine, because of our present lack of safe and effective therapy for diseases such as CLD (10) . Neutrophil functions, long thought to be final effector processes in the acute inflammatory response, now are known to include self-amplifying proinflammatory functions, e.g. the release of chemokines (3). Our present study for the first time demonstrates the dose-related potency of IL-10 in the inhibition of neutrophil chemokine release when neutrophils of the newborn are stimulated by endotoxin. This inhibition did not occur to the same degree when they were stimulated by TNF; however, had a larger number of studies been performed, a partial inhibition by IL-10 may have been detectable. Because potential antiinflammatory therapy could be targeted against transcriptional activation of chemokines, we studied NF-B, a pivotal proinflammatory transcription factor (7) whose activity is associated with neutrophil chemokine release in the newborn (9) . Surprisingly, IL-10 did not inhibit NF-B activity in the neutrophil of the newborn under our experimental conditions.
Neutrophils are the first inflammatory cells to be recruited into the airways of newborns developing CLD (1, 2) . The presence of chemokines such as IL-8 and MIP in the airway of infants with a high likelihood of developing CLD suggests that resident lung cells and neutrophils recruited into the lung initiate the acute inflammatory response (5, 6). There are now four classes of chemokines as defined by positioning of cysteine; IL-8 is part of the CXC chemokine class and MIP is part of the CC chemokine class. Accordingly, our experiments evaluated neutrophil release of two structurally different chemokines that have clinical relevance and are known to be potent stimulants of neutrophil chemotaxis in lung diseases of the newborn (5, 6) .
In the present study we found that when neutrophils were stimulated with LPS, a nearly maximal inhibition of chemokine release was observed with IL-10 at a dose of 1 ng/mL. Previous studies have examined IL-10 concentrations in bronchoalveolar lavage fluid from preterm infants ventilated for respiratory distress syndrome. In one study IL-10 was not detectable in the lungs of preterm infants (12) . In a recent study, IL-10 concentrations rose in bronchoalveolar lavage from premature infants up to 5 d after birth; concentrations in the range of 0.1 to 1 ng/mL were detected (17) . Both previous studies indicate that because of low levels of endogenous IL-10, for a short-lived period of time, premature infants with CLD may lack the antiinflammatory effect provided by IL-10.
Extrapolating our in vitro data suggests that supplementing with exogenous IL-10 to blood or alveolar levels in the 1-ng/mL range may hypothetically provide antiinflammatory protection to infants developing CLD. However, the following questions arise. First, do monocytes/macrophages or other airway cells of the newborn respond similarly to neutrophils with respect to IL-10 inhibition of chemokine release? And second, how important is TNF (18) as a stimulator of chemokine release in the airways of premature infants developing CLD? Although IL-10 did not inhibit TNF-induced chemokine release from neutrophils, our previous work demonstrated that dexamethasone did, at concentrations that are probably much lower than achieved when standard dexamethasone regimens are used clinically for the treatment of CLD (15) . It is unknown whether IL-10 and dexamethasone have synergistic effects on chemokine release from cells that can release proinflammatory mediators.
There have been no previous studies in the newborn addressing the mechanism by which IL-10 suppresses proinflammatory chemokine release. During the last decade, increasing evidence has demonstrated that NF-B is a pivotal transcription factor associated with a variety of proinflammatory mediators and apoptosis pathways in a variety of cells (7) . In the neutrophil, specifically, NF-B is bound to an inhibitory protein (I-B␣) that is localized in the nucleus (8) . I-B␣ phosphorylation results in ubiquitination and rapid degradation of I-B␣ by the proteosome, leading to NF-B binding to DNA (7) . In the present studies, we confirmed NF-B activation with I-B␣ degradation when neutrophils were exposed to LPS or TNF; IL-10 had no effect on NF-B activation, measured directly by EMSA or measured indirectly by Western blot analysis of I-B␣ degradation, up to 3 h after neutrophil stimulation. By 3 h after stimulation of neutrophils with LPS, I-B␣ had been totally resynthesized. IL-10 had no effect on The mechanisms of IL-10 inhibition of chemokine production by neutrophils need greater clarification. Studies involving neutrophils from adults indicate that gene transcription, mRNA destabilization, and de novo induction of a repressor protein may be involved (19 -21) . The transcriptional control of chemokine expression is complex and appears to involve multiple protein kinase cascades and several transcription factors such as NF-B and activating protein-1, as well as the formation of multiprotein complexes, which interact with DNA (21) . Recent studies have shown that in human neutrophils from adults, IL-10 induces phosphorylation and activation of the transcription factor Stat 3, and up-regulates mRNA synthesis of the suppressor of cytokine signaling-3 (SOCS-3) (16, 22) . Interestingly, however, the Stat 3 phosphorylation and SOCS-3 mRNA synthesis are more dependent on the expression levels of IL-10 receptor (IL-10R1), and more significantly enhanced after neutrophil stimulation with LPS for a few hours (16) .
Whether there are developmental differences in IL-10 control of chemokine release, which explains why NF-B activity was unaffected in our experiments, remains to be determined. Studies from our laboratory have demonstrated that there are developmental differences in IL-8 production (PMNs from newborns releasing IL-8 to a greater degree than PMNs from adults) and associated NF-B activity (3, 9) . In addition, recent studies have shown maturational differences in the regulation of another transcription factor, activating protein-1 (23, 24) , as well as in the expression of cell-surface receptors (25) (26) (27) .
Endogenous IL-10 can act as a local, antiinflammatory cytokine, limiting inflammation as shown in animal experiments in which there is a disrupted IL-10 gene or administration of IL-10 antibody, leading to increased neutrophil recruitment, chemokine release, and worsening of disease (28, 29) . Conversely, recombinant human IL-10, delivered s.c., has been shown to be safe and effective in patients with inflammatory disorders such as mild to moderately active Crohn's disease (13) . Because there may be a relative deficiency of IL-10 in CLD, and because IL-10 is a potent inhibitor of chemokine release in the neutrophil of the newborn stimulated by LPS, we suggest that further work should be directed to the possibility of using exogenous IL-10 in the treatment of CLD. In addition, a better understanding of the underlying mechanisms accounting for antiinflammatory action of IL-10 may also lead to safer and more effective therapy for CLD compared with corticosteroids.
